A review of drug options in age-related macular degeneration therapy and potential new agents.
Age-related macular degeneration (AMD) is the leading cause of legal blindness in people > 50 years of age in the developed world. AMD is both a debilitating and costly disease for the individual and the community. Greater understanding of the mechanisms and pathways involved in causing the visual loss in AMD has resulted in the advent of several newer and more effective treatment options, making it an exciting time in the management of AMD. This paper will examine the principles behind the existing drug therapies available, as well as those being developed in the management or prophylaxis of AMD and its vision-threatening complications.
Yeoh
Jonathan
J
Centre for Eye Research Australia, The University of Melbourne, Australia.
Sims
Joanne
J
Guymer
Robyn H
RH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001766:Blindness / Q000209:etiology / Q000517:prevention & control*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D017075:Laser Coagulation; D008268:Macular Degeneration / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D010778:Photochemotherapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A